SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:su-80062"
 

Sökning: id:"swepub:oai:DiVA.org:su-80062" > Glucagon-like pepti...

Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats

Darsalia, Vladimer (författare)
Karolinska Institutet,Karolinska institutet
Mansouri, Shiva (författare)
Karolinska Institutet,Karolinska institutet
Ortsater, Henrik (författare)
Karolinska Institutet,Karolinska institutet
visa fler...
Olverling, Anna (författare)
Karolinska Institutet,Karolinska institutet
Nozadze, Nino (författare)
Karolinska Institutet,Karolinska institutet
Kappe, Camilla (författare)
Karolinska Institutet,Karolinska institutet
Iverfeldt, Kerstin (författare)
Stockholms universitet,Institutionen för neurokemi,Stockholms universitet, Institutionen för neurokemi
Tracy, Linda M. (författare)
Stockholms universitet,Institutionen för neurokemi,Stockholms universitet, Institutionen för neurokemi
Grankvist, Nina (författare)
Karolinska institutet
Sjöholm, Åke (författare)
Karolinska Institutet,Karolinska institutet
Patrone, Cesare (författare)
Karolinska Institutet,Karolinska institutet
visa färre...
 (creator_code:org_t)
Portland Press, 2012
2012
Engelska.
Ingår i: Clinical Science. - : Portland Press. - 0143-5221 .- 1470-8736. ; 122:9-10, s. 473-483
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Diabetes is a strong risk factor for premature and severe stroke. The GLP-IR (glucagon-like peptide-1 receptor) agonist Ex-4 (exendin-4) is a drug for the treatment of T2D (Type 2 diabetes) that may also have neuroprotective effects. The aim of the present study was to determine the efficacy of Ex-4 against stroke in diabetes by using a diabetic animal model, a drug administration paradigm and a dose that mimics a diabetic patient on Ex-4 therapy. Furthermore, we investigated inflammation and neurogenesis as potential cellular mechanisms underlying the Ex-4 efficacy. A total of seven 9-month-old Type 2 diabetic Goto-Kakizaki rats were treated peripherally for 4 weeks with Ex-4 at 0.1, 1 or 5 mu g/kg of body weight before inducing stroke by transient middle cerebral artery occlusion and for 2-4 weeks thereafter. The severity of ischaemic damage was measured by evaluation of stroke volume and by stereological counting of neurons in the striatum and cortex. We also quantitatively evaluated stroke-induced inflammation, stem cell proliferation and neurogenesis. We show a profound anti-stroke efficacy of the clinical dose of Ex-4 in diabetic rats, an arrested microglia infiltration and an increase of stroke-induced neural stem cell proliferation and neuroblast formation, while stroke-induced neurogenesis was not affected by Ex-4. The results show a pronounced anti-stroke, neuroprotective and anti-inflammatory effect of peripheral and chronic Ex-4 treatment in middle-aged diabetic animals in a preclinical setting that has the potential to mimic the clinical treatment. Our results should provide strong impetus to further investigate GLP-IR agonists for their neuroprotective action in diabetes, and for their possible use as anti-stroke medication in non-diabetic conditions.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinsk bioteknologi -- Biomedicinsk laboratorievetenskap/teknologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Medical Biotechnology -- Biomedical Laboratory Science/Technology (hsv//eng)

Nyckelord

exendin-4 (Ex-4)
Goto-Kakizaki (GK) rat
middle cerebral artery occlusion (MCAO)
neurogenesis
neuroprotection

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy